来自MSN1 年
US FDA's 6 observations for Cipla's Patalganga unit drags firm's shares down 1.5%
Troubles rose again for Cipla Ltd as the US Food and Drug Administration slapped a form 483 with six inspectional observations on the drugmaker's manufacturing facility at Patalganga in Maharashtra.